What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?

Basit Öğe Kaydı
dc.contributor.authorBakirci, S.
dc.contributor.authorSolmaz, D.
dc.contributor.authorAl Osaimi, N.
dc.contributor.authorDalkilic, E.
dc.contributor.authorCan, M.
dc.contributor.authorErden, A.
dc.contributor.authorOzisler, C.
dc.date.accessioned2024-02-23T14:49:16Z
dc.date.available2024-02-23T14:49:16Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractObjective Minimal disease activity (MDA) is an important target in patients with psoriatic arthritis (PsA), however it is also criticised for having a low threshold for patient reported outcomes (PRO). The aim of the study was to assess the prevalence of MDA and its components in patients with PsA and to evaluate disease characteristics and patterns in patients with or without MDA (MDA(+) or MDA(-)). Methods PsArt-ID (Psoriatic Arthritis-International Database) is a prospective, multicentre web-based registry. PsA patients who had at least 1 year of disease duration and had full data for MDA were included for this analysis (n=317). Patients were considered in MDA+ when they met at least 5/7 of the MDA criteria. Results MDA was achieved in 46% patients. Within MDA- patients, body surface area (51.2%) and swollen joint count (53.5%) domains could still be achieved in the majority and 93.5% of them had no enthesitis using the Leeds enthesitis index. Of 170 patients with MDA-, 90 patients did not fulfill all 3 PROs of MDA. Mono-arthritis subtype (RR: 2.01), absence of enthesitis (RR: 1.570) and absence of distal interphalangeal (DIP) joint disease (RR: 1.1) were associated with higher probability of achieving MDA. Conclusion The MDA criteria provide an objective target for treatment in trials and clinical practice; however, in real life PROs are the most significant barriers to achieve MDA. The presence of DIP joints disease makes it difficult to reach MDA due to active PROs.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK); Turkish Rheumatology Association (TRD); Union Chimique Belge (UCB)en_US
dc.description.sponsorshipS. Bakirci received funding from The Scientific and Technological Research Council of Turkey (TUBITAK) and Turkish Rheumatology Association (TRD). D. Solmaz received funding from Union Chimique Belge (UCB) for axial fellowship. S. Z. Aydin received honoraria from Abbvie, Novartis, UCB, Pfizer, Sanofi and Celpere. The other co-authors have declared no competing interests.en_US
dc.identifier.endpage812en_US
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue5en_US
dc.identifier.pmid30767863en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage808en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/18079
dc.identifier.volume37en_US
dc.identifier.wosWOS:000485817300014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinical & Exper Rheumatologyen_US
dc.relation.ispartofClinical And Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPsoriatic Arthritisen_US
dc.subjectMinimal Disease Activityen_US
dc.subjectPatient-Reported Outcomesen_US
dc.titleWhat are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu